Kornimate/medical-research-clean huggingface dataset:
the detection of circulating tumor cells (ctcs) in patients with prostatic cancer undergoing cryosurgery combined with dc-cik treatment

Conditions: Neoplastic Cells, Circulating

Summary: circulating tumor cells (ctcs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. enumeration and molecular characterization of ctcs in prostatic cancer could play an important role in diagnosis, predicting the risk for tumor recurrence, and providing novel target therapy biomarkers. in view of these facts, the investigators wanted to demonstrate the value of multiparameter flow cytometry in detecting human tumor cells of prostatic cancer in normal peripheral blood after cryosurgery with or without dendritic cell(dc)-cytokine-induced killers(cik) treatment, and the investigators also compared the specificity with reverse transcriptase polymerase chain reaction (rt-pcr) method.

1 day before and 2 days after cryosurgery with or without dc-cik treatment，approximately 17-ml ethylene diamine tetraacetic acid(edta)-blood was drawn by vein puncture from patients with prostatic cancer and healthy volunteers. the blood of the healthy volunteers will be used to evaluate the sensitivity and specificity and as negative control cells. to avoid contamination with skin cells, 2 ml blood will be discarded before the study samples will be taken.briefly, the mononucleate cells will be separated from the blood over ficoll- paque for 20 min with 1800g at 4℃. the interface cells will be removed and washed, and the red blood cells(rbcs) will be removed using a lysis buffer followed by a repeated wash. the mononuclear cells will be counted and aliquot for rt-pcr and multiparameter flow cytometry on the basis of at least 2-3×106 cells for each methodology. the cell pellet will be resuspended in phosphate-buffered saline for multiparameter flow cytometry and in trizol reagent for rt-pcr. aim : identification of ctcs may lead to better diagnosis and prognosis and could help to choose an adequate therapy.

Eligibility criteria:
inclusion criteria: 1. age:18-75 2. karnofsky performance status \>60 3. diagnosis of prostatic cancer based on histology or the current accepted radiological measures. 4. classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ 5. will receive cryosurgery and/or dc-cik treatment 6. life expectancy: greater than 3 months 7. patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. patients with other primary tumor except prostatic cancer 2. history of coagulation disorders or anemia

Keywords: prostatic neoplasms circulating tumor cells
diazepam at the active phase of labor

Conditions: Pain; Prolonged Labour

Summary: prolonged labour can lead to increased maternal and neonatal mortality and morbidity due to increased risks of maternal exhaustion, postpartum haemorrhage and sepsis, fetal distress and asphyxia and requires early detection and appropriate clinical response. the risks for complications of prolonged labour are much greater in poor resource settings. active management of labour versus physiological, expectant management, has shown to decrease the occurrence of prolonged labour. administering sedatives during labour could also lead to faster and more effective dilatation of the cervix. interventions to shorten labour, such as sedatives, can be used as a preventative or a treatment strategy in order to decrease the incidence of prolonged labour. as the evidence to support this is still largely anecdotal around the world. (cochrane database of systematic reviews 2013,cd009243.pub3.; cochrane database of systematic reviews 2012, cd009223.pub2.) hypothesis: diazepam reduced the duration of labor and the severity of pain in labor.


Eligibility criteria:
inclusion criteria: * primigravida * at term * singleton pregnancy * cephalic presentation * spontaneous labour * intact membranes at the beginning of active phase exclusion criteria: * induced labour * spontaneous rupture of membranes at randomisation * obstetric complications, or medical complications * previous uterine scarring, or cervical surgery * cervical dilatation of more than 5 cm * other antispasmodics in the first stage * malpresentation, macrosomia, cephalopelvic disproportion

Keywords: diazepam active phase
functional connectome in prader-willi syndrome: neuroimaging and ai to assess therapeutic impact

Conditions: Prader Willi Syndrome; Hyperphagia; Behavior Disorders

Summary: the goal of this observational study is to explore brain network changes and identify patterns related to hyperphagia, hormonal treatment effects, and cognitive deficits in adults with prader-willi syndrome (pws). the main questions it aims to answer are: * how are brain connectivity patterns altered in pws patients compared to healthy and obese controls? * how do brain network changes relate to hyperphagia and the response to growth hormone therapy? researchers will compare pws patients to healthy and obese controls to see if there are significant differences in brain network connectivity before and after meals and growth hormone therapy. ultimately, researchers will try to develop predictive models of treatment outcomes using ai and machine learning.

prader-willi syndrome (pws) is a rare genetic condition marked by issues like constant hunger, obesity, hormonal imbalances, and cognitive difficulties. while studies have shown changes in brain connectivity in pws patients, a complete understanding of these changes is still lacking. this project aims to explore brain network patterns in pws using advanced ai techniques to better understand the impact of hyperphagia, hormonal treatments, and cognitive challenges. this study will combine data from brain functional magnetic ressonance imaging (fmri)), genetic data, hormonal levels, and clinical details; of 39 adults with pws and 82 control participants (including 52 healthy and 30 obese controls). all participants are matched for age, sex, and bmi where applicable. fmri data has been obtained before and after meals, and/or before and after one year of growth hormone therapy. data quality will be assessed and summarize it using averages or percentages. then, groups will be statistically compared to detect patterns related to hyperphagia and gh therapy. regarding brain connectivity, data from patients and controls will be compared, tracking how brain networks change after meals/gh therapy and applying advanced statistical methods to control errors. finally, using ai, models to predict treatment outcomes and brain network changes will be developed. these models will be tested and refined using different techniques to ensure reliability. with this research, expected results are to identify unique brain patterns in pws, uncover how these relate to symptoms like hyperphagia, and develop ai models to predict treatment outcomes. ultimately, this research aims to improve our understanding of pws and help develop better treatments.

Eligibility criteria:
inclusion criteria: * genetically confirmed diagnosis of prader-willi syndrome. * age older than 18 years old. exclusion criteria: * age younger than 18 years old. * contraindications for fmri. * visual defects.

Keywords: neuroimage artificial intelligence prader-willi syndrome
effect of rifampin on pharmacokinetics of sitaxsentan

Conditions: Pulmonary Arterial Hypertension

Summary: this study will assess how rifampin will affect the blood levels of sitaxsentan. safety of sitaxsentan given alone and with rifampin will also be assessed.


Eligibility criteria:
inclusion criteria: * healthy male subjects and/or women of non-child bearing potential. * subjects between the ages of 21 and 55 years, inclusive. * signed informed consent. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. * has hepatic dysfunction. * has history of excessive alcohol and tobacco use.

Keywords: sitaxsentan rifampin drug interaction pharmacokinetics
does end-fire technique increase detection rate of prostate cancer at first re-biopsy compared to side-fire technique?

Conditions: Prostate Cancer

Summary: prostate cancer is the most common cancer among men in sweden. during investigation of suspected cancer transrectal ultrasound with needle biopsies from prostate leeds to diagnosis. the most common technique today is side-fire where the needle enter the prostate in angle from the probe. in end-fire technique the needle enters the prostate at tip of probe without angle. the difference in techniques side-fire vs. end-fire affects the possibility to reach the ventral and apical aspects of prostate. today´s standard is at least five cores from each side of the prostate at first biopsy. if first sample is negative there will usually be another urological exam and a first re-biopsy. the study aim to compare these two methods in cancer detection. the investigators' hypothesis is that when using end-fire technique at first re-biopsy, investigators find more cancers compared to side-fire. patients are prospectively randomized into two groups, both assessing 12 core biopsies according to study protocol. primary endpoint is cancer detection. data will be collected about patient age, psa-level, prostate size, digital rectal exam, hypoechogenic zones and length of cancers.


Eligibility criteria:
inclusion criteria: * first re-biopsy * psa over 3ng/ml * t1c to t2a palpatory finding exclusion criteria: * prostate cancer * t2b or more advanced cancer * more than one previous biopsy done

Keywords: biopsy technique transrectal ultrasonography probe side-fire prostate cancer end-fire
observational safety study in subjects with type 2 diabetes mellitus starting or switching to biphasic insulin aspart 30 treatment

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in europe. the aim of this study is to investigate safety and efficacy in subjects with type 2 diabetes mellitus starting or switching to biphasic insulin aspart 30 (novomix® 30) treatment.


Eligibility criteria:
inclusion criteria: * subjects with type 2 diabetes
oxytocin and social decision making in schizophrenia

Conditions: Schizophrenia

Summary: schizophrenia patients and healthy volunteers will be included. subjects who meet the inclusion and exclusion criteria for the study will be recruited. after completion of clinical assessments and neuropsychological assessments, all subjects will undergo two fmri scans. in one scan subjects will receive a single dose of intranasal oxytocin and in another scan, they will receive intranasal saline. the order of administration of oxytocin or saline will be counterbalanced so that they are not administered in the same order to all subjects. subjects will be blind to the drug administered.


Eligibility criteria:
schizophrenia group - inclusion criteria: 1. males between 18 and 45 years with at least 7 years of education 2. the dsm-iv diagnosis of schizophrenia or schizoaffective or schizophreniform disorder 3. capacity to provide informed consent exclusion criteria: 1. current comorbid dsm-iv axis i diagnosis 2. general impaired intellectual functioning 3. history of alcohol or substance abuse or dependence in the last 12 months 4. contraindication to oxytocin like hypersensitivity, vascular disease, chronic nephritis, epilepsy, asthma 5. past history of head injury resulting in loss of consciousness or neurosurgery 6. concomitant severe medical conditions 7. metal implants or paramagnetic objects within the body or claustrophobia which may interfere with the mri. healthy volunteers: inclusion criteria: 1. males between 18 and 45 years with at-least 7 years education 2. capacity to provide informed consent 3. absence of past or present psychiatric illnesses including substance abuse/dependence exclusion criteria: 1. general impaired intellectual functioning 2. contraindication to oxytocin like hypersensitivity, vascular disease, chronic nephritis, epilepsy, asthma 3. past history of head injury resulting in loss of consciousness or neurosurgery 4. concomitant severe medical conditions 5. metal implants or paramagnetic objects within the body or claustrophobia which may interfere with the mri. 6. family history of schizophrenia or schizoaffective or schizophreniform disorder in a first-degree relative
perioperative mental health in orthopedic surgery

Conditions: Orthopedic Surgery; Older Adults; Depression; Anxiety

Summary: this hybrid 1 study will test the effectiveness of a bundled intervention comprised of behavioral activation and medication optimization in reducing symptoms of depression and anxiety in older adults undergoing orthopedic surgery (compared with usual care), while examining implementation outcomes.


Eligibility criteria:
inclusion criteria: * adults ≥ 60 years * scheduled primary hip or primary knee arthroplasty procedure * phq-ads ≥ 10, indicating clinically significant depression or anxiety symptoms exclusion criteria: * barrier to communication (unable to read, speak, and understand english) * severe cognitive impairment screened by the sbt (short blessed test) \>10 * acutely suicidal * previous participation in this study or another cpmh study of the intervention bundle or its feasibility.

Keywords: behavioral: behavioral activation medication optimization care as usual
the function of pa, rbp and trsf in malnutrition detecting and nutritional status monitoring for npc patients

Conditions: Nasopharyngeal Carcinoma; Malnutrition

Summary: the purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma patients with chemoradiotherapy.


Eligibility criteria:
inclusion criteria: * newly histologic diagnosis of nasopharyngeal carcinoma(who ii/iii) * all genders，range from 18～60 years old * karnofsky performance status(kps) ≥ 80 * clinical stage iii\~ivb(uicc 8th) * without significant digestive system disease，nutritional and metabolic diseases or endocrine disease * without significant cardiac，respiratory，kidney or liver disease * not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy) * white blood cell(wbc) count ≥ 4×109/l, neutrophile granulocyte(ne) count ≥ 1.5×109/l, hemoglobin(hgb) ≥ 10g/l, platelet(plt) count ≥ 100×109/l * alanine aminotransferase (alt) or aspartate aminotransferase(ast) \< 1.5×upper limit of normal(uln), bilirubin \< 1.5×uln, alanine aminotransferase (ccr) ≥ 30ml/min * inform consent form exclusion criteria: * distance metastases * second malignancy within 5 years * drug or alcohol addition * do not have full capacity for civil acts * active systemic infections * chronic consumptions * mental disorder * pregnancy or lactation * concurrent immunotherapy or hormone therapy for other diseases * severe complication, eg, uncontrolled hypertension

Keywords: pre-albumin retinol conjugated protein transferrin locoregionally advanced nasopharyngeal carcinoma nutrition
betaseron 16-year long-term follow-up (ltf) in patients with relapsing-remitting multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis (ms) and possibly the long-term effects of betaseron in the patients who were previously enrolled in the original north american study that led to the marketing approval of betaseron.

this study has previously been posted by berlex, inc. berlex, inc. has been renamed to bayer healthcare pharmaceuticals, inc.bayer healthcare pharmaceuticals, inc. is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * patients in north america have to have been previously enrolled in the original betaseron trial from 1988-1993 * be able to understand the consent form (or have a guardian who can) exclusion criteria: * north american patients cannot be included if they have not participated in the original betaseron trial from 1988-1993
study venetoclax effectiveness and real-life treatment management in participants with chronic lymphocytic leukemia

Conditions: Cancer - Chronic Lymphocytic Leukemia

Summary: this study will evaluate real-life effectiveness and use in participants starting venetoclax treatment for chronic lymphocytic leukemia (cll).


Eligibility criteria:
inclusion criteria: * participants with diagnosed chronic lymphocytic leukemia (cll) and eligible for venetoclax as per label. * participants for whom the physician has decided to initiate cll treatment with venetoclax. * participants the physician believes he can personally follow over all the study period. * participants who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control. exclusion criteria: - participating in a clinical trial with an investigative drug for cll within 30 days prior to treatment initiation.

Keywords: venetoclax venclyxto cancer chronic lynmphocytic leukemia (cll)
glycemic monitoring in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: current guidelines on the diagnoses and management of cystic fibrosis (cf) related diabetes recommend treatment for diabetes based on diagnostic criteria derived from adults with type 2 diabetes. increasing evidence supports treating early glucose abnormalities in cystic fibrosis patients to target cf specific outcomes, including lung function and nutrition (bmi-body mass index). however, the criteria and timing of when to start insulin therapy in the 'prediabetic' state are unclear. a more accurate characterization of blood sugar variability in youth with and without cf will help the investigators better interpret continuous glucose monitor (cgm) findings in patients with cf prediabetes and diabetes and more accurately identify those individuals at greatest risk for disease progression.


Eligibility criteria:
inclusion criteria: healthy controls (n=45) - 1. age 10-25 years 2. bmi \<85th percentile 3. baseline health at enrollment cf controls (n=45) - 1. age 10-25 years 2. diagnosis of cystic fibrosis (by newborn screen, sweat chloride testing, or genetic testing) 3. baseline health at enrollment (no inclusion/exclusion criteria for cf patients based on lung function, bmi, pancreatic insufficiency, or genotype) cf prediabetes \& cfrd (n=70) 1. age 10-25 years 2. diagnosis of cystic fibrosis (by newborn screen, sweat chloride testing, or genetic testing) 3. history of abnormal oral glucose tolerance testing (2h-glucose \>140, fasting plasma glucose \>100,1hr glucose \>200) 4. if taking medication that affects glucose metabolism (ex. insulin, insulin sensitizers, glucocorticoids, atypical antipsychotics), should be on a stable dose over the past 3 months exclusion criteria: healthy controls - 1. known diagnosis of diabetes or prediabetes (including type 1, type 2, mody), abnormal oral glucose tolerance test (ogtt) (ie. fasting plasma glucose ≥100 or 2hr ≥140 mg/dl) or hba1c ≥ 5.7% 2. bmi ≥85th percentile 3. chronic disease that may affect glucose metabolism or use of medications affecting glucose metabolism in the past 3 months (ex. insulin, insulin sensitizers, glucocorticoids, atypical antipsychotics) 4. presence of type 1 diabetes auto-antibodies in any individuals with a first degree relative with type 1 diabetes (will only include first degree relatives if they have had previous negative auto-antibody screening performed as part of participation in other studies such as the trial net studies at the barbara davis center) 5. acute illness (ex. asthma exacerbation, gastroenteritis, febrile illness) 6. pregnancy cf participants - 1. diagnosis of type 1 diabetes, type 2 diabetes, or mody 2. varying doses of medication affecting glucose metabolism in the past 3 months 3. pulmonary exacerbation associated with hospitalization, or systemic steroid requirement in the preceding 6 weeks 4. pregnancy

Keywords: cystic fibrosis healthy controls diabetes cystic fibrosis related diabetes (cfrd) cfrd
my medihealth: a paradigm for children-centered medication management

Conditions: Asthma

Summary: the last mile of the medication use system requires tools to help patients comply with medication administration rules and monitor for side effects. personal health records (phr) and emerging user-adopted communication tools promise to change the landscape of medication management. the overarching goal of the mymedihealth project is to investigate ways in which phrs and supported applications can improve the safety and quality of medication delivery. preliminary work in this area by a team of parents, patients and school/clinic health providers created a vision for mymedihealth, a next-generation medication management system. mymedihealth was envisioned to allow home-based, school-based, and other caregivers to ensure safe and effective medication delivery. this vision featured just-in-time medication reminders to children with special health care needs, two-way communication to log when doses have been administered or when side effects have occurred, and mechanisms to warn caregivers about side effects and drug interactions. however, much of this work was done using prototypes, storyboards, and vision videos. recognizing that this vision cannot be carried out without significant changes in processes and policies, the purpose of this proposed study is to evaluate the impact of medication management tools such as mymedihealth on medication adherence for children with chronic illnesses. specifically, the investigators hypothesize that compared with usual practice, children using mymedihealth will have improved medication adherence and will report improved (decreased) asthma symptoms.


Eligibility criteria:
inclusion criteria: * access to the internet caregiver agrees to let child use the internet for the project internet service working properly legal guardian approves of study child with her or his own cell phone exclusion criteria: * non english or spanish speaking family